突觸核蛋白α(SNCa)多克隆抗體(生物素標記)
Biotin-Linked Polyclonal Antibody to Synuclein Alpha (SNCa)
SNC-A; aSYN; PD1; PARK1; PARK4; NACP; Non-A Beta Component Of Alzheimer's Disease Amyloid Precursor Protein; Non-A4 component of amyloid precursor
- 編號LAB222Hu71
- 物種Homo sapiens (Human，人)相同的名稱，不同的物種。
- 來源抗體標記
- Ig類型IgG
- 純化方式抗原特異性親和純化
- 標記物生物素
- 原抗體PAB222Hu01-突觸核蛋白α(SNCa)多克隆抗體
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 濃度500μg/mL
- 且適物種-
- 應用WB; IHC; ICC.
如果抗體需用于流式細胞術，請參見流式抗體。 - 下載英文說明書 中文說明書
- 規(guī)格20μl100μl200μl1ml10ml
- 價格¥ 659¥ 1537¥ 2196¥ 5490¥ 21960
- 欲了解實際交易價格和更多情況，請與當地經銷商聯系!
產品包裝(模擬)
產品包裝(模擬)
通過ISO 9001、ISO 13485質量體系認證
特異性
該抗體是針對SNCa的兔多克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別SNCa。
用法
Western blotting: 0.5-2ug/ml
Immunocytochemistry in formalin fixed cells: 5-20ug/ml
Immunohistochemistry in formalin fixed frozen section: 5-20ug/ml
Immunohistochemistry in paraffin section: 5-20ug/ml
Enzyme-linked Immunosorbent Assay: 0.05-2ug/ml
Optimal working dilutions must be determined by end user.
儲存
經常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產生。保質期內，在適當的條件下存儲，損失率低于5%。
贈品
增值服務
相關產品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPB222Hu01 | 突觸核蛋白α(SNCa)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB222Hu01 | 突觸核蛋白α(SNCa)多克隆抗體 | WB; IHC; ICC; IP. |
| LAB222Hu71 | 突觸核蛋白α(SNCa)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| MAB222Hu22 | 突觸核蛋白α(SNCa)單克隆抗體 | WB; IHC; ICC; IP. |
| SEB222Hu | 突觸核蛋白α(SNCa)檢測試劑盒(酶聯免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| AEB222Hu | 抗突觸核蛋白α抗體(Anti-SNCa)檢測試劑盒(酶聯免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
參考文獻
| 雜志 | 參考文獻 |
| The Journal of Clinical Investigation | Cerebrospinal fluid–based kinetic biomarkers of axonal transport in monitoring neurodegeneration[PubMed: PMC3428100] |
| Neurobiology of Disease | Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission[PubMed: PMC3107939] |
| Nature Communications | Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus[PubMed: PMC3265381] |
| Provisional chapter | Mutations of PARK Genes and Alpha-Synuclein and Parkin Concentrations in Parkinson’s Disease[Intechopen:Source] |
| Nerodegeneration | Apolipoprotein Eε4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairment[pubmed:29326545] |
| Experimental gerontology | The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling.[pubmed:29107062] |
| Neurobiology of Disease | Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity[Pubmed: 30521842] |
| molecular and cellular biochemistry | Potential therapeutic effects of antagonizing adenosine A2A receptor, curcumin and niacin in rotenone-induced Parkinson's disease mice model[Pubmed: 31820278] |
| International Journal of Pharmacology | Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease[Pubmed: 32084576] |
| EBioMedicine | Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys[Pubmed: 32810825] |